Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
18 Novembre 2021 - 1:00PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, has announced a symposium and poster
presentations at the 14th International Congress of Inborn Errors
of Metabolism (ICIEM), November 21-23, 2021, Sydney, Australia.
“We are pleased to present this important data
at the ICIEM conference, demonstrating statistically significant
correlation between toxic galactitol level and disease severity,”
said Shoshana Shendelman, Chief Executive Officer of Applied
Therapeutics. “Additionally, new data on burden of illness in
adults with Galactosemia demonstrates that the disease continues to
progress through adulthood and has substantial impact of quality of
life.”
Presentation Details
Poster #504:
Progressive Worsening of the Central Nervous System
Phenotype in Children with Classic Galactosemia on Galactose
Restricted Diet: A Cross-Sectional Analysis
Poster #573:
Qualitative Interviews of Adults with Classic Galactosemia
(CG) and their Caregivers: Disease Burden and Challenges with Daily
Living
Poster #574: Galactitol Level is a
Predictor of Disease Severity in Children with Classic Galactosemia
on Galactose Restricted Diet
Symposium: Targeting Toxic Galactitol
for the Treatment of Classic Galactosemia
- Date and Time: November 23, 1:30 – 2:30 PM AEDT
- Speakers: Shoshana Shendelman, CEO and Founder of Applied
Therapeutics; Riccardo Perfetti, Chief Medical Officer at Applied
Therapeutics; Laura Saltonstall, VP, Medical Affairs at Applied
Therapeutics
About Applied Therapeutics
Applied Therapeutics is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need. The Company’s lead drug candidate, AT-007,
is a novel central nervous system penetrant Aldose Reductase
Inhibitor (ARI) for the treatment of CNS rare metabolic diseases,
including Galactosemia, SORD Deficiency and PMM2-CDG. The Company
is also developing AT-001, a novel potent ARI, for the treatment of
Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
The preclinical pipeline also includes AT-003, an ARI designed to
cross through the back of the eye when dosed orally, for the
treatment of Diabetic retinopathy, as well as novel dual PI3k
inhibitors in preclinical development for orphan oncology
indications.
To learn more, please visit
www.appliedtherapeutics.com and follow the company on Twitter
@Applied_Tx.
Forward-Looking Statements
This press release contains “forward-looking
statements” that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. Any statements, other than
statements of historical fact, included in this press release
regarding strategy, future operations, prospects, plans and
objectives of management, including words such as “may,” “will,”
“expect,” “anticipate,” “plan,” “intend,” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) are forward-looking statements.
Forward-looking statements in this release involve substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by the forward-looking
statements, and we, therefore cannot assure you that our plans,
intentions, expectations or strategies will be attained or
achieved.
Such risks and uncertainties include, without
limitation, Factors that may cause actual results to differ from
those expressed or implied in the forward-looking statements in
this press release are discussed in our filings with the U.S.
Securities and Exchange Commission, including the “Risk Factors”
contained therein. Except as otherwise required by law, we disclaim
any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Contacts
Investors:Maghan Meyers(212)
600-1902 orappliedtherapeutics@argotpartners.com
Media:media@appliedtherapeutics.com Applied
Therapeutics, Inc.
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Lug 2023 a Lug 2024